Peter de Blank, MD, MSCE
- Co-Medical Director, Brain Tumor Center
- Professor, UC Department of Pediatrics
- peter.deblank@cchmc.org
- Board Certified
About
Biography
I graduated from the University of California, San Francisco School of Medicine with a concentration in Medical Education. I completed my residency in Pediatrics, and fellowships in Pediatric Hematology & Oncology and Pediatric Neuro-Oncology at the Children’s Hospital of Philadelphia. During my fellowship training, I also completed a Master of Science in Clinical Epidemiology and Biostatistics at the University of Pennsylvania. After completing my training, I became a faculty member at University Hospitals Rainbow Babies & Children’s Hospital in Cleveland in 2012. In 2017, I joined the faculty at Cincinnati Children’s as a member of the Pediatric Neuro-Oncology program.
As a pediatric neuro-oncologist, I care for children with brain tumors and specialize in central nervous system tumors, including neurofibromatosis type 1 (NF1) and NF1-related tumors. My research focuses on investigating tissue microstructure in pediatric brain tumors through non-invasive imaging techniques such as MR relaxometry and diffusion tensor imaging.
I have been elected by peers for inclusion in the Best Doctors in America List.
BA: Stanford University, Stanford, CA, 1997
BS: Chemistry, Stanford University, Stanford, CA, 1997
MA: Stanford University, Stanford, CA, 1997
MD: Emphasis in Medical Education, University of California, San Francisco School of Medicine, San Francisco, CA, 2005
Internship: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2006
Residency: Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2008
MS: Clinical Epidemiology, University of Pennsylvania, Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, 2011
Fellowship: Pediatric Hematology and Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2011
Fellowship: Pediatric Neuro-Oncology, The Children’s Hospital of Philadelphia, Philadelphia, PA, 2012
Interests
Pediatric neuro-oncology; neurofibromatosis type 1 (NF1); NF1-associated brain tumors
Services and Specialties
Interests
Cancer imaging; diffusion tensor imaging; MR relaxometry; magnetic resonance fingerprinting; developmental therapeutics
Research Areas
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Cumulative dose of chemotherapy and survival outcomes in children with average-risk medulloblastoma treated on Children's Oncology Group study ACNS0331. Neuro-Oncology. 2026; 28(7):1772-1780.
ID #476 Increased Prevalence of Optic Nerve Hypoplasia in Neurofibromatosis Type 1. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.170.
ID #1028 A Retrospective Review Characterizing the Toxicities, Outcomes, and Molecular Characteristics of Adolescent and Young Adult Patients with Medulloblastoma. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.457.
ID #1002 Hematologic Toxicity during Proton Radiation: a Review of Weekly CBC Results at a Single Center. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.440.
ID #141 The Use of MEK Inhibitors for Neurofibromatosis Type 1-Associated High Grade Glioma and High-Grade Astrocytoma with Piloid Features in Children and Young Adults: A Real-World Cohort Analysis. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.032.
ID #1132 CONNECT TarGeT-A molecularly-guided phase 2 trial for children and young adults newly diagnosed with high-grade glioma (HGG), including diffuse intrinsic pontine glioma (DIPG): (1) Ribociclib and everolimus for HGG/DIPG with cell cycle and/or PI3K/mTOR pathway alterations, and (2) Ribociclib and temozolomide for diffuse hemispheric glioma (DHG), H3G34-mutant. Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.514.
ID #1122 Preliminary feasibility of an international, multidisciplinary central screening platform for the CONNECT TarGeT molecularly-guided phase 2 umbrella trial for children and young adults with newly-diagnosed high-grade glioma (HGG) including diffuse intrinsic pontine glioma (DIPG) Neuro-Oncology Pediatrics. 2026; 2(Supplement_1):wuag026.507.
Tempered Optimism: Advances in the Precision Medicine Era for Pediatric Low-Grade Glioma. Neuro-Oncology. 2026.
Multi-Institutional Annotated Multiparametric MRI Dataset of Pediatric High-Grade Gliomas. Radiology: Artificial Intelligence. 2026; 8(3):e250902.
MEK inhibitors for neurofibromatosis type 1-associated central and peripheral nervous system tumors. Neuro-Oncology Advances. 2026; 8(Suppl 2):ii14-ii24.
From the Blog
Improved Chemotherapy and Surgery Eliminating Need for Radiation for Low-Grade Gliomas
Peter de Blank, MD, MSCE3/4/2024
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey